Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells

S. W. Kim, R. D. Beauchamp, Courtney Townsend, J. C. Thompson

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Vasoactive intestinal polypeptide (VIP) is a gut neuroendocrine polypeptide that increases cyclic adenosine monophosphate (cAMP) production in cells with VIP receptors. Some gastrointestinal cancer cells possess functional receptors for VIP; however, the role of VIP in regulation of growth of gastric cancer cells has not been determined. The purpose of this study was to determine whether VIP and other agents that increase cAMP regulate growth of a human gastric cancer cell line (AGS) and whether these agents regulate expression of c-myc proto-oncogene, which is required for cell proliferation. We measured levels of cAMP by radioimmunoassay, and we used Northern blot analysis to examine c-myc messenger RNA expression. Cell- growth studies were carried out in media supplemented with 3% serum, and cells were counted with a Coulter counter. We found that VIP significantly increased cAMP production of AGS cells in a dose-dependent manner, whereas secretin, glucagon, and peptide histidine methionine (PHM) did not stimulate cAMP production. Exogenous cAMP (8-bromo-cAMP) inhibited AGS cell growth in a dose-dependent manner. VIP acted synergistically with either isobutylmethyl- xanthine or forskolin to inhibit AGS cell proliferation. The increased c-myc expression, which was induced by serum, was inhibited by simultaneous treatment with VIP and isobutylmethyl-xanthine. We have found that AGS cells have specific, functional VIP receptors (activation of which are negatively correlated with cell growth) and that the mechanism by which VIP acts to inhibit cell growth appears to be due, in part, to cAMP-dependent regulation of c-myc proto-oncogene expression.

Original languageEnglish (US)
Pages (from-to)270-276
Number of pages7
JournalSurgery
Volume110
Issue number2
StatePublished - 1991

Fingerprint

Vasoactive Intestinal Peptide
Stomach
Carcinoma
Cyclic AMP
Growth
myc Genes
Xanthine
Stomach Neoplasms
Peptide PHI
Cell Proliferation
8-Bromo Cyclic Adenosine Monophosphate
Gastrointestinal Neoplasms
Secretin
Colforsin
Glucagon
Serum
Northern Blotting
Radioimmunoassay
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Surgery

Cite this

Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. / Kim, S. W.; Beauchamp, R. D.; Townsend, Courtney; Thompson, J. C.

In: Surgery, Vol. 110, No. 2, 1991, p. 270-276.

Research output: Contribution to journalArticle

Kim, S. W. ; Beauchamp, R. D. ; Townsend, Courtney ; Thompson, J. C. / Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. In: Surgery. 1991 ; Vol. 110, No. 2. pp. 270-276.
@article{17371eaafa86452b95943be313b6f512,
title = "Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells",
abstract = "Vasoactive intestinal polypeptide (VIP) is a gut neuroendocrine polypeptide that increases cyclic adenosine monophosphate (cAMP) production in cells with VIP receptors. Some gastrointestinal cancer cells possess functional receptors for VIP; however, the role of VIP in regulation of growth of gastric cancer cells has not been determined. The purpose of this study was to determine whether VIP and other agents that increase cAMP regulate growth of a human gastric cancer cell line (AGS) and whether these agents regulate expression of c-myc proto-oncogene, which is required for cell proliferation. We measured levels of cAMP by radioimmunoassay, and we used Northern blot analysis to examine c-myc messenger RNA expression. Cell- growth studies were carried out in media supplemented with 3{\%} serum, and cells were counted with a Coulter counter. We found that VIP significantly increased cAMP production of AGS cells in a dose-dependent manner, whereas secretin, glucagon, and peptide histidine methionine (PHM) did not stimulate cAMP production. Exogenous cAMP (8-bromo-cAMP) inhibited AGS cell growth in a dose-dependent manner. VIP acted synergistically with either isobutylmethyl- xanthine or forskolin to inhibit AGS cell proliferation. The increased c-myc expression, which was induced by serum, was inhibited by simultaneous treatment with VIP and isobutylmethyl-xanthine. We have found that AGS cells have specific, functional VIP receptors (activation of which are negatively correlated with cell growth) and that the mechanism by which VIP acts to inhibit cell growth appears to be due, in part, to cAMP-dependent regulation of c-myc proto-oncogene expression.",
author = "Kim, {S. W.} and Beauchamp, {R. D.} and Courtney Townsend and Thompson, {J. C.}",
year = "1991",
language = "English (US)",
volume = "110",
pages = "270--276",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells

AU - Kim, S. W.

AU - Beauchamp, R. D.

AU - Townsend, Courtney

AU - Thompson, J. C.

PY - 1991

Y1 - 1991

N2 - Vasoactive intestinal polypeptide (VIP) is a gut neuroendocrine polypeptide that increases cyclic adenosine monophosphate (cAMP) production in cells with VIP receptors. Some gastrointestinal cancer cells possess functional receptors for VIP; however, the role of VIP in regulation of growth of gastric cancer cells has not been determined. The purpose of this study was to determine whether VIP and other agents that increase cAMP regulate growth of a human gastric cancer cell line (AGS) and whether these agents regulate expression of c-myc proto-oncogene, which is required for cell proliferation. We measured levels of cAMP by radioimmunoassay, and we used Northern blot analysis to examine c-myc messenger RNA expression. Cell- growth studies were carried out in media supplemented with 3% serum, and cells were counted with a Coulter counter. We found that VIP significantly increased cAMP production of AGS cells in a dose-dependent manner, whereas secretin, glucagon, and peptide histidine methionine (PHM) did not stimulate cAMP production. Exogenous cAMP (8-bromo-cAMP) inhibited AGS cell growth in a dose-dependent manner. VIP acted synergistically with either isobutylmethyl- xanthine or forskolin to inhibit AGS cell proliferation. The increased c-myc expression, which was induced by serum, was inhibited by simultaneous treatment with VIP and isobutylmethyl-xanthine. We have found that AGS cells have specific, functional VIP receptors (activation of which are negatively correlated with cell growth) and that the mechanism by which VIP acts to inhibit cell growth appears to be due, in part, to cAMP-dependent regulation of c-myc proto-oncogene expression.

AB - Vasoactive intestinal polypeptide (VIP) is a gut neuroendocrine polypeptide that increases cyclic adenosine monophosphate (cAMP) production in cells with VIP receptors. Some gastrointestinal cancer cells possess functional receptors for VIP; however, the role of VIP in regulation of growth of gastric cancer cells has not been determined. The purpose of this study was to determine whether VIP and other agents that increase cAMP regulate growth of a human gastric cancer cell line (AGS) and whether these agents regulate expression of c-myc proto-oncogene, which is required for cell proliferation. We measured levels of cAMP by radioimmunoassay, and we used Northern blot analysis to examine c-myc messenger RNA expression. Cell- growth studies were carried out in media supplemented with 3% serum, and cells were counted with a Coulter counter. We found that VIP significantly increased cAMP production of AGS cells in a dose-dependent manner, whereas secretin, glucagon, and peptide histidine methionine (PHM) did not stimulate cAMP production. Exogenous cAMP (8-bromo-cAMP) inhibited AGS cell growth in a dose-dependent manner. VIP acted synergistically with either isobutylmethyl- xanthine or forskolin to inhibit AGS cell proliferation. The increased c-myc expression, which was induced by serum, was inhibited by simultaneous treatment with VIP and isobutylmethyl-xanthine. We have found that AGS cells have specific, functional VIP receptors (activation of which are negatively correlated with cell growth) and that the mechanism by which VIP acts to inhibit cell growth appears to be due, in part, to cAMP-dependent regulation of c-myc proto-oncogene expression.

UR - http://www.scopus.com/inward/record.url?scp=0026333272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026333272&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 270

EP - 276

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -